The liver is the most common site of metastasis in patients with colorectal cancer (1-5). We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the primary tumor, and in metastasis to the CNS (6-8). Measuring total transcription with RNA-sequencing and microarray in metastasis and the cancer (primary tumor) from which they are derived enables rational design and development of novel chemotherapies with optimized therapeutic index (9). Here we utilize whole transcriptome technologies (10, 11) to measure total transcription in the liver metastases of humans with colorectal cancer. We describe a therapeutic target that is up-regulated and differentially expressed in liver metastasis in humans with colorectal cancer, KDM6A, as a candidate therapeutic target for the medical management of liver metastasis in human colorectal cancer.